[The significance of chemotherapy for survival after recurrent breast cancer. A population based study of patients treated in the 1950's, 1960's and 1970's].
In a population-based study survival after recurrence was compared in three cohorts of patients each with a primary diagnosis of breast cancer in either 1959, 1969 end 1979. The use of chemotherapy after recurrence in these cohorts was either none, sporadic or widespread. This allowed a retrospective analysis of the survival impact of chemotherapy. Our data suggest that chemotherapy in recurrent breast cancer prolongs survival by 9.5 months in patients who survive more than two weeks from the start of treatment for their recurrence, given the basic assumption that the natural history of breast cancer and the influence of endocrine therapy have not changed significantly during the 20-year period covered by the study.
Cold
S
S
Onkologisk afdeling R., Odense Universitetshospital.
Jensen
N V
NV
Brincker
H
H
Rose
C
C
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality*; D015331:Cohort Studies; D003718:Denmark / Q000453:epidemiology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
Betydningen af kemoterapi for overlevelsen ved recidiverende brystkraeft. Et populationsbaseret studie over patienter behandlet i 1950'erne, 1960'erne og 1970'erne.